Coimbatore, August 19 : Invesco Mutual Fund announced the launch of Invesco India Pharma and Healthcare Fund (An open ended equity scheme investing in Pharma, Healthcare and allied sectors). The fund seeks to capitalize on India’s evolving healthcare ecosystem, which is being shaped by favourable demographics, expanding healthcare access, rising insurance penetration, growing global pharmaceutical leadership, and emerging innovation-driven opportunities across healthcare and life sciences. The scheme will invest across pharmaceutical companies, hospitals, diagnostics, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), medical devices, healthcare services, insurance and other allied healthcare segments. The fund will be managed by Aditya Khemani and will be benchmarked against the BSE Healthcare TRI. Speaking at the launch, Aditya Khemani, Head of Equity & Fund Manager, Invesco Mutual Fund, said “India’s healthcare sector is undergoing a structural transformation. The country is not only witnessing rising healthcare consumption driven by favourable demographics and increasing affordability but is also strengthening its position as a global pharmaceutical and healthcare innovation hub. We see attractive opportunities across domestic pharma, hospitals, diagnostics, CDMOs and emerging healthcare segments that can potentially benefit from this multi-year growth cycle. Our investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem.”The minimum lumpsum investment amount during the NFO is ₹1,000/- and in multiples of ₹1/- thereafter. For SIP investments, the minimum application amount is ₹100/- and in multiples of ₹1/- thereafter. The fund will charge an exit load of 0.50% for units redeemed/switched out on or before 3 months from the date of allotment. No exit load will be charged if units are redeemed/switched out after 3 months. The New Fund Offer (NFO) is open for subscription from today (August 18, 2026) and will close on September 1, 2026.